emerging trials in melanoma: swog s1801, opacin-neo and prado
Published 5 months ago • 64 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
1:54
opacin-neo and prado: personalized neoadjuvant io for melanoma based on pathologic response
-
2:33
opacin-neo & prado 3-year results in stage iii melanoma: personalized neoadjuvant io benefits
-
1:30
omission of adjuvant therapy and tlnd in melanoma: insights from opacin-neo, prado, and nadina
-
1:39
opacin and opacin-neo: neoadjuvant immunotherapy for advanced melanoma
-
0:37
swog s1801: pathologic response in neoadjuvant-adjuvant vs. adjuvant pembro for resectable melanoma
-
1:40
swog s1801: benefits of neoadjuvant immunotherapy for patients with resectable melanoma
-
2:24
prado: personalized response-driven therapy in resectable stage iii melanoma
-
0:57
circulating immune cell subsets in patients with melanoma from the opacin-neo trial
-
3:28
neoadjuvant therapy in melanoma: the prado trial - 2022 program: melanoma video library
-
4:02
prado: personalized response-driven surgery and adjuvant therapy in stage iii melanoma
-
3:09
advances in utilizing neoadjuvant immunotherapy in melanoma
-
2:43
clinical & tumor characteristics of patients with recurrent melanoma upon immunotherapy
-
1:33
georgina long, esmo 2022: highlights in melanoma – swog s1801 trial
-
1:00
ongoing and future melanoma trials
-
1:14
adjuvant and neoadjuvant clinical trials for melanoma
-
2:39
shallow wgs vs conventional cytogenetic analysis for diagnosing and stratifying mds
-
10:42
what is new in melanoma?
-
25:50
melanoma | 2022 oneoncology conference